1810869-23-8
1810869-23-8
Chemical Structure
MK-8527
- CAS No.: 1810869-23-8
- Formula:C13H13ClN4O3
- Molecular Weight:308.72
InChIKey: QNBRWIDODCWXKA-IGJMFERPSA-N
SMILES: OC[C@]1(C#C)[C@@H](O)C[C@H](N2C3=NC(Cl)=NC(N)=C3C=C2)O1
Biological Activity: MK-8527 is an orally active HIV inhibitor and nucleoside reverse transcriptase translocation inhibitor (NRTTI) with antiviral activity. MK-8527 has a similar inhibitory mechanism to ISL (HY-104012)[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MK-8527 | 99.02% | MK-8527 is an orally active HIV inhibitor and nucleoside reverse transcriptase translocation inhibitor (NRTTI) with antiviral activity. MK-8527 has a similar inhibitory mechanism to ISL (HY-104012). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gillespie SW, et al. Islatravir: evaluation of clinical development for HIV and HBV. Expert Opin Investig Drugs. 2024 Feb;33(2):85-93. [Content Brief]
- [2]. Liu AY, et al. CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases. Top Antivir Med. 2024 Jul 17;32(3):447-482. [Content Brief]
- [3]. Gunaratne SH, et al. CROI 2024: The Challenges of Sustained Viral Suppression, Advanced HIV Disease, and Ending the HIV Epidemic Targets. Top Antivir Med. 2024 Aug 12;32(4):542-567. [Content Brief]
- [4]. Zhernov YV, et al. Microbicides for Topical HIV Immunoprophylaxis: Current Status and Future Prospects. Pharmaceuticals (Basel). 2024 May 22;17(6):668. [Content Brief]
Keywords
